News
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
325last 24h
1819last 7d
322🟢 bullish (7d)
188🔴 bearish (7d)
129publishers
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
The U.S. FDA recently highlighted Amgen’s role in its real‑time clinical trials initiative, confirming the initiation of Amgen’s Phase 1b STREAM-SCLC study in limited-stage small cell lung cancer using real-time data signal sharing. This positions Amgen at the forefront of emerging “continuous” trial frameworks that aim to shorten development timelines and could change how oncology drugs are tested and reviewed. We’ll now examine how Amgen’s early involvement in real-time oncology trials...
Amgen (NasdaqGS:AMGN) has been selected by the US Food and Drug Administration to participate in its real time clinical trials initiative. The company will apply the framework to its Phase 1b STREAM SCLC trial in small cell lung carcinoma. The initiative enables the FDA to receive trial data signals in real time, with the goal of improving trial efficiency and drug development timelines. Amgen focuses on biotechnology driven therapies, including oncology, where clinical trial design and...
Amgen announced a $300 million expansion of its U.S. biologics manufacturing network. The plan includes a significant new investment in a Puerto Rico facility to scale next generation technologies. The move is intended to support domestic medicine production and strengthen the American supply chain. For investors tracking NasdaqGS:AMGN, this manufacturing build out adds an operational angle to a stock that is currently trading at $329.59. Over the past year, the share price return of 25.7%...
RPRX vs. AMGN: Which Stock Is the Better Value Option?
Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
The agency accused Amgen of manipulating data for its fast-growing drug Tavneos and wants it pulled from the market, but the large pharma is digging its heels in.
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street H
The additional investment builds on $650 million Amgen committed to its Juncos facility last year, which supplies medicines to more than 60 countries
Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.